210 related articles for article (PubMed ID: 35074585)
1. Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.
Wang YT; Zhang NN; Liu LJ; Jiang H; Hu D; Wang ZZ; Chen NH; Zhang Y
Biochem Biophys Res Commun; 2022 Feb; 594():46-56. PubMed ID: 35074585
[TBL] [Abstract][Full Text] [Related]
2. Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects.
Donello JE; Banerjee P; Li YX; Guo YX; Yoshitake T; Zhang XL; Miry O; Kehr J; Stanton PK; Gross AL; Burgdorf JS; Kroes RA; Moskal JR
Int J Neuropsychopharmacol; 2019 Mar; 22(3):247-259. PubMed ID: 30544218
[TBL] [Abstract][Full Text] [Related]
3. Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms.
Kato T; Duman RS
Pharmacol Biochem Behav; 2020 Jan; 188():172827. PubMed ID: 31733218
[TBL] [Abstract][Full Text] [Related]
4. Rapastinel, an NMDAR positive modulator, produces distinct behavioral, sleep, and EEG profiles compared with ketamine.
Banerjee P; Donello JE; Hare B; Duman RS
Behav Brain Res; 2020 Aug; 391():112706. PubMed ID: 32461133
[TBL] [Abstract][Full Text] [Related]
5. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects.
Fogaça MV; Fukumoto K; Franklin T; Liu RJ; Duman CH; Vitolo OV; Duman RS
Neuropsychopharmacology; 2019 Dec; 44(13):2230-2238. PubMed ID: 31454827
[TBL] [Abstract][Full Text] [Related]
6. The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.
Moskal JR; Burgdorf JS; Stanton PK; Kroes RA; Disterhoft JF; Burch RM; Khan MA
Curr Neuropharmacol; 2017; 15(1):47-56. PubMed ID: 26997507
[TBL] [Abstract][Full Text] [Related]
7. Synaptic mechanisms underlying rapid antidepressant action of ketamine.
Kavalali ET; Monteggia LM
Am J Psychiatry; 2012 Nov; 169(11):1150-6. PubMed ID: 23534055
[TBL] [Abstract][Full Text] [Related]
8. Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants.
Kato T
Neuropharmacology; 2023 Feb; 223():109325. PubMed ID: 36334763
[TBL] [Abstract][Full Text] [Related]
9. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.
Yang B; Zhang JC; Han M; Yao W; Yang C; Ren Q; Ma M; Chen QX; Hashimoto K
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3647-57. PubMed ID: 27488193
[TBL] [Abstract][Full Text] [Related]
10. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.
Burgdorf J; Zhang XL; Weiss C; Gross A; Boikess SR; Kroes RA; Khan MA; Burch RM; Rex CS; Disterhoft JF; Stanton PK; Moskal JR
Neuroscience; 2015 Nov; 308():202-11. PubMed ID: 26343295
[TBL] [Abstract][Full Text] [Related]
11. Targeting metaplasticity mechanisms to promote sustained antidepressant actions.
Brown KA; Gould TD
Mol Psychiatry; 2024 Apr; 29(4):1114-1127. PubMed ID: 38177353
[TBL] [Abstract][Full Text] [Related]
12. A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance.
Su S; Kay G; Hochadel T; Rojo J; Christopher Stein J; Boinpally R; Periclou A
Clin Transl Sci; 2022 Jan; 15(1):255-266. PubMed ID: 34423904
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
14. NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine.
Zanos P; Brown KA; Georgiou P; Yuan P; Zarate CA; Thompson SM; Gould TD
J Neurosci; 2023 Feb; 43(6):1038-1050. PubMed ID: 36596696
[TBL] [Abstract][Full Text] [Related]
15. The role of eEF2 kinase in the rapid antidepressant actions of ketamine.
Suzuki K; Monteggia LM
Adv Pharmacol; 2020; 89():79-99. PubMed ID: 32616215
[TBL] [Abstract][Full Text] [Related]
16. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
Wang J; Jing L; Toledo-Salas JC; Xu L
Neurosci Bull; 2015 Feb; 31(1):75-86. PubMed ID: 25488282
[TBL] [Abstract][Full Text] [Related]
17. GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.
Liu RJ; Duman C; Kato T; Hare B; Lopresto D; Bang E; Burgdorf J; Moskal J; Taylor J; Aghajanian G; Duman RS
Neuropsychopharmacology; 2017 May; 42(6):1231-1242. PubMed ID: 27634355
[TBL] [Abstract][Full Text] [Related]
18. Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression.
Pereira VS; Joca SRL; Harvey BH; Elfving B; Wegener G
Acta Neuropsychiatr; 2019 Oct; 31(5):258-265. PubMed ID: 31230597
[TBL] [Abstract][Full Text] [Related]
19. Acute Amino Acid d-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms.
Wei IH; Chen KT; Tsai MH; Wu CH; Lane HY; Huang CC
J Agric Food Chem; 2017 Dec; 65(49):10792-10803. PubMed ID: 29161812
[TBL] [Abstract][Full Text] [Related]
20. Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.
Widman AJ; McMahon LL
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):E3007-E3016. PubMed ID: 29531088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
